Efficacy and long-term outcomes of palivizumab prophylaxis to prevent respiratory syncytial virus infection in infants with cystic fibrosis in Northern Ireland-Reference-Cited by-同舟云学术

Efficacy and long-term outcomes of palivizumab prophylaxis to prevent respiratory syncytial virus infection in infants with cystic fibrosis in Northern Ireland

Published:2016-01-25 Issue:4 Volume:51 Page:379-385
ISSN:8755-6863
Container-title:Pediatric Pulmonology
language:en
Short-container-title:Pediatr Pulmonol.

Author:

Groves H.E.¹,Jenkins L.²,Macfarlane M.²,Reid A.²,Lynn F.³,Shields M.D.⁴

Affiliation:

1. Department of Paediatrics; Royal Belfast Hospital for Sick Children; Belfast United Kingdom

2. Department of Cystic Fibrosis; Royal Belfast Hospital for Sick Children; Belfast United Kingdom

3. School of Nursing and Midwifery; Queen's University Belfast; Belfast United Kingdom

4. Department of Paediatrics; Queens University of Belfast; Belfast United Kingdom

Funder

None reported

Publisher

Wiley

Subject

Pulmonary and Respiratory Medicine,Pediatrics, Perinatology, and Child Health

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/ppul.23376/fullpdf

Reference31 articles.

1. Timing of monoclonal antibody for seasonal RSV prophylaxis in the United Kingdom;Goddard;Epidemiol Infect,2007

2. Contribution of RSV to bronchiolitis and pneumonia-associated hospitalizations in English children, April 1995-March 1998;Muller-Pebody;Epidemiol Infect,2002

3. Driscoll Children's Hospital respiratory syncytial virus database: risk factors, treatment, and hospital course in 3,308 infants and young children, 1991-2002;Purcell;Pediatr Infect Dis J,2004

4. Health care utilisation of prematurely born, preschool children related to hospitalisation for RSV infection;Greenough;Arch Dis Child,2004

5. Lower respiratory tract infections among human immunodeficiency virus-exposed, uninfected infants;Mussi-Pinhata;IntJ Infect Dis,2010

Cited by 19 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Introduction on Monoclonal Antibodies;Monoclonal Antibodies;2021-06-23

2. Bacterial and Viral Coinfections with the Human Respiratory Syncytial Virus;Microorganisms;2021-06-13

3. Challenges in the prevention or treatment of RSV with emerging new agents in children from low- and middle-income countries;Expert Review of Anti-infective Therapy;2020-12-08

4. Expert consensus on palivizumab use for respiratory syncytial virus in developed countries;Paediatric Respiratory Reviews;2020-02

5. Palivizumab and Long-term Outcomes in Cystic Fibrosis;Pediatrics;2019-07-01